Pfizer to withdraw global marketing applications to conduct new trial

Pfizer, Inc. will globally withdraw all dalbavancin marketing applications, which include the U.S. new drug application and the European marketing authorization application. The applications, withdrawn after feedback from regulatory committees, were for the treatment of complicated skin and skin structure infections in adults. Pfizer plans to conduct an additional clinical trial with dalbavancin.